Phase II Study of Preoperative Concurrent Chemoradiation Therapy With S-1 in Patients With T4 Oral Squamous Cell Carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 5, 2010, Pages 1347-1352

  Nomura, Tomoko ^a   Murakami, Ryuji ^a   Toya, Ryo ^a   Teshima, Keiko ^a   Nakahara, Aya ^a   Hirai, Toshinori ^a   Hiraki, Akimitsu ^a   Nakayama, Hideki ^a   Yoshitake, Yoshihiro ^a   Ota, Kazutoshi ^a   Obayashi, Takehisa ^a   Yamashita, Yasuyuki ^a   Oya, Natsuo ^a   Shinohara, Masanori ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemoradiation therapy; Oral cancer; Radiosensitizer; S 1

Indexed keywords

ACUTE TOXICITY; ADVERSE EVENTS; CHEMORADIATION; CONCURRENT CHEMORADIATION; MUCOSITIS; NEUTROPENIA; ORAL CANCER; OVERALL SURVIVAL RATES; PATHOLOGIC RESPONSE; PHASE II; RADIOSENSITIZERS; REGIONAL FAILURES; SQUAMOUS CELL CARCINOMA; SURGICAL INTERVENTIONS; TOTAL DOSE; TUMOR CONTROL;

RADIOTHERAPY; TUMORS;

TOXICITY;

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MALE; MORBIDITY; MOUTH CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RASH; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; OXONIC ACID; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TEGAFUR; TREATMENT FAILURE;

EID: 77949545583     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.03.055     Document Type: Article

References (29)

1. Mohr C., Bohndorf W., Carstens J., et al. Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone: A prospective, multicentric, randomized DOSAK study of advanced squamous cell carcinoma of the oral cavity and the oropharynx (a 3-year follow-up). Int J Oral Maxillofac Surg 23 (1994) 140-148
2. Klug C., Berzaczy D., Voracek M., et al. Preoperative chemoradiotherapy in the management of oral cancer: A review. J Craniomaxillofac Surg 36 (2008) 75-88
3. Kessler P., Grabenbauer G., Leher A., et al. Neoadjuvant and adjuvant therapy in patients with oral squamous cell carcinoma: Long-term survival in a prospective, non-randomized study. Br J Oral Maxillofac Surg 46 (2008) 1-5
4. Kirita T., Ohgi K., Shimooka H., et al. Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: An analysis of long-term results. Oral Oncol 35 (1999) 597-606
5. Eich H.T., Löschcke M., Scheer M., et al. Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity: Outcome of 134 patients. Strahlenther Onkol 184 (2008) 23-29
6. Wanebo H., Chougule P., Ready N., et al. Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol 8 (2001) 644-650
7. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
8. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
9. Al-Sarraf M. Treatment of locally advanced head and neck cancer: Historical and critical review. Cancer Control 9 (2002) 387-399
10. Murakami R., Nishimura R., Baba Y., et al. Concurrent chemoradiation therapy with low-dose CDDP and UFT for glottic carcinomas: Evaluation using the sixth edition of the UICC TNM staging system. Acta Oncol 45 (2006) 162-167
11. Kato H., Ichinose Y., Ohta M., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
12. Malet-Martino M., and Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 7 (2002) 288-323
13. Inoue S., Ohtani H., Tsujimoto M., et al. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. Drug Metab Pharmacokinet 22 (2007) 162-168
14. Shirasaka T., Shimamato Y., Ohshimo H., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 (1996) 548-557
15. Kawahara M., Furuse K., Segawa Y., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85 (2001) 939-943
16. Van den Brande J., Schoffski P., Schellens J.H., et al. EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer 88 (2003) 648-653
17. Tsukuda M., Kida A., Fujii M., et al. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93 (2005) 884-889
18. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (2007) 1810-1820
19. Harada K., Kawaguchi S., Supriatno, et al. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 40 (2004) 713-719
20. Nakagawa T., Otsuki N., Masai Y., et al. Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts. Acta Otolaryngol 128 (2008) 936-940
21. Sudo K., Yamaguchi T., Ishihara T., et al. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 67 (2007) 219-224
22. Tsuji H., Kiba T., Nagata M., et al. A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. Oncology 71 (2006) 369-373
23. Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol 13 (2008) 112-116
24. Sato T., Kokuba Y., Koizumi W., et al. Phase I trial of neoadjuvant preoperative chemotherapy with S-1 and irinotecan plus radiation in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 69 (2007) 1442-1447
25. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
26. Shimosato Y., Oboshi S., and Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1 (1971) 19-35
27. Klug C., Wutzl A., Kermer C., et al. Preoperative radiochemotherapy and radical resection for stages II to IV oral and oropharyngeal cancer: Grade of regression as crucial prognostic factor. Int J Oral Maxillofac Surg 34 (2005) 262-267
28. Ishii A., Korogi Y., Hirai T., et al. Intraarterial infusion chemotherapy and conformal radiotherapy for cancer of the mouth: Prediction of the histological response to therapy with magnetic resonance imaging. Acta Radiol 48 (2007) 900-906
29. 18F]FDG-PET predicts local tumour control and survival in advanced oral squamous cell carcinoma. Oral Oncol 39 (2003) 170-177